Venus Concept Inc Stock Price, News & Analysis

Venus Concept (NASDAQ: VERO) has successfully completed its previously announced registered direct offerings, raising total gross proceeds of approximately $2.7 million. The latest offering closed with the sale of 386,700 shares of common stock at $4.06 per share, generating approximately $1.57 million. This follows a previous offering that closed on April 10, 2025, which raised approximately $1.15 million.

The offerings were conducted as registered direct offerings priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. serving as the exclusive placement agent. The medical aesthetic technology company plans to use the net proceeds for general corporate purposes. The shares were offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on November 1, 2024.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has announced a registered direct offering of 386,700 shares of common stock priced at $4.06 per share. The offering, priced at-the-market under Nasdaq rules, is expected to generate gross proceeds of approximately $1.5 million before deducting placement agent fees and expenses.

The closing is anticipated around April 14, 2025, subject to customary conditions. H.C. Wainwright & Co. serves as the exclusive placement agent. The company plans to use the net proceeds for general corporate purposes. The offering is made pursuant to an effective S-3 shelf registration statement previously filed with the SEC.

Venus Concept (NASDAQ: VERO) has successfully closed its previously announced registered direct offering, raising approximately $1.1 million in gross proceeds through the sale of 328,573 shares of common stock. The shares were priced at $3.50 per share at-the-market under Nasdaq rules.

H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The medical aesthetic technology company plans to utilize the net proceeds, after deducting placement agent fees and other offering expenses, for general corporate purposes. The offering was conducted through a shelf registration statement on Form S-3 that received SEC effectiveness on November 1, 2024.

Venus Concept (NASDAQ: VERO) has announced a registered direct offering of 328,573 shares of common stock priced at $3.50 per share, expected to raise approximately $1.1 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules.

The closing is anticipated around April 10, 2025, subject to customary conditions. H.C. Wainwright & Co. serves as the exclusive placement agent. The company plans to use the net proceeds for general corporate purposes. The offering is made pursuant to an effective S-3 shelf registration statement previously filed with the SEC.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled the release of its first quarter fiscal year 2025 financial results for Thursday, May 15, 2025, before market opening. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session.

Interested participants can join via phone using the access code 13753054: domestic callers can dial 877-407-2991, while international callers should use 201-389-0925. A live webcast will be available on the company's investor relations website. A two-week replay will be accessible using the same access code: 877-660-6853 for domestic and 201-612-7415 for international callers.

Venus Concept (NASDAQ: VERO) has executed a significant debt-to-equity exchange transaction with Madryn Asset Management. The company converted $11.0 million of subordinated convertible notes into 379,311 shares of Series Y preferred stock on March 31, 2025.

This strategic move has substantially improved Venus Concept's financial position, reducing its total debt obligations to approximately $35.5 million. This represents a 54% reduction from $76.7 million as of March 31, 2024, and an 11% decrease from $39.7 million as of December 31, 2024.

The transaction is part of Venus Concept's ongoing efforts to optimize its capital structure and create additional balance sheet flexibility, supporting the company's journey toward sustained, long-term growth and profitability.

Venus Concept (NASDAQ: VERO) reported its Q4 and FY 2024 financial results, showing mixed performance amid industry challenges. Q4 revenue declined 13% year-over-year to $15.8 million, while operating expenses decreased 11%. The company reduced its debt by 47% from $74.9 million to $39.7 million in FY2024.

Key highlights include a Q4 GAAP net loss improvement of 28% year-over-year, though Adjusted EBITDA loss increased slightly to $6.1 million. The company expanded its international distributor network and successfully completed a 1-for-11 reverse stock split, regaining Nasdaq compliance. Additionally, Venus Concept secured an additional $10.0 million financing capacity through an amended Bridge Loan Agreement with Madryn.

For FY2024, total revenue decreased 15% to $64.8 million, with net loss attributable to stockholders at $47.0 million. The company expects Q1 2025 revenue of at least $14.0 million but is not providing full-year guidance due to ongoing strategic alternatives evaluation.

Venus Concept (NASDAQ: VERO), a global medical aesthetic technology leader, has scheduled the release of its fourth quarter and fiscal year 2024 financial results for March 31, 2025, before market opening.

The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested participants can dial 877-407-2991 (201-389-0925 for international callers) using access code 13751985. A live webcast will be available on the company's investor relations website, with a two-week replay period available afterward.

Venus Concept Inc. (NASDAQ: VERO) announced a 1-for-11 reverse stock split effective March 3, 2025, at 5:00 p.m. EST. Trading on the split-adjusted basis will begin March 4, 2025, on the Nasdaq Capital Market. The split was approved by stockholders on February 14, 2025, with an authorized ratio range of 1-for-5 to 1-for-16.

The primary goal is to increase the bid price to regain Nasdaq compliance. The company's CUSIP number will change to 92332W303, while maintaining the 'VERO' trading symbol. Every 11 shares will be automatically reclassified into one new share, with proportionate adjustments to warrants, convertible securities, and equity incentive plans. Stockholders entitled to fractional shares will receive rounded-up whole shares, with no cash payments for fractions.